Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version).
10.3760/cma.j.cn501113-20230419-00176-1
- Collective Name:Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association;;Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases
- Publication Type:Journal Article
- Keywords:
Diagnosis;
Drug-induced liver injury;
Guidelines;
Management;
Treatment
- MeSH:
Humans;
Chemical and Drug Induced Liver Injury/therapy*;
Drug-Related Side Effects and Adverse Reactions;
Liver Failure, Acute;
Dietary Supplements/adverse effects*;
Risk Factors
- From:
Chinese Journal of Hepatology
2023;31(4):355-384
- CountryChina
- Language:Chinese
-
Abstract:
Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, anti-neoplastic drugs), and signal and assessment of DILI in clinical trials.
